Source: Gallup Management talent exists in every company. It's often hiding in plain sight. Gallup has found that one of the most important decisions companies make is simply whom they name manager. Yet our analytics suggest they usually get it wrong. In fact, Gallup finds that companies fail to choose…...
Court ruling against FDA enables more combination products to be classified as devices
Source: FierceBiotech In victory for industry, FDA's second attempt to classify Prevor's skin wash as a device is vacated once again. The U.S. District Court for the District of Columbia rejected the FDA's attempt to classify Prevor's Diphoterine Skin Wash as a drug rather than a device for the second…...
AbbVie partners with Google’s Calico on $1.5B R&D operation focused on aging
Source: FierceBiotech Hot on the heels of its $805 million development deal with Infinity, AbbVie Pharmaceuticals ($ABBV) has followed up today with a plan to partner with Google's ($GOOG) closely watched biotech upstart Calico on a new research operation that will cost up to $1.5 billion to get started. Google-backed…...
Big Pharma doesn’t win the margin stakes. That’s Jazz, Celgene, Regeneron and Alexion
Source: Margins, margins, margins. That's an inevitable mantra among top investors and analysts. Just ask Novartis ($NVS) CEO Joe Jimenez, who's pledged big improvements in the Swiss drugmaker's spread. Or Eli Lilly ($LLY) CFO Derica Rice, who's had to explain why his company can promise to maintain margins as its…...
Cubist Pharmaceuticals: Ripe For Acquisition?
Source: Bidness ETC Threats from the increase in drug-resistant germs, and the subsequent rise in demand for more effective and high-impact antibiotics has spurred interest in companies such as Cubist Pharmaceuticals Inc (CBST). The Massachusetts-based drug developer has announced that it plans to introduce four new medicines to the market…...
After a 6-year delay, Medicines Co. bags FDA approval for once-troubled antibiotic
Source: FierceBiotech More than 5 years after The Medicines Company ($MDCO) bagged Targanta and its troubled antibiotic oritavancin for the bargain basement rate of $42 million plus potential bonus payments, the biotech has finally nailed down an elusive FDA approval of the product for skin infections caused by Gram-positive bacteria,…...
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in the United States
Source: PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that it has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's drug KERYDINTM (tavaborole) topical solution, 5% in the United States. PharmaDerm, the branded dermatology business of…...
AbbVie finally gets Shire, its low tax base and enough new drugs to protect its future
Source: With a bid reaching nearly $55 billion and some goodies for the top execs, AbbVie ($ABBV) was finally able to get Ireland-based Shire ($SHPG) to surrender its independence, a portfolio of attention deficit hyperactivity disorder and rare disease drugs, and its low Irish tax base. Shire shareholders get £52.48…...
LEO Pharma strikes global dermatology deal with KLOK Tech
Source: Danish dermatology specialist LEO Pharma and Canada's KLOX Technologies, both privately-held companies, have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX's BioPhotonic technology platform in dermatology. The accord between the companies includes a "European Conformity" CE approved treatment for moderate…...
Novartis to license Google “smart lens” technology
Source: FierceBiotech Innovative technology offers potential to transform eye care and further enhance Alcon's leadership in contact lenses and intraocular lenses Agreement is a first step for Novartis to evolve technology to manage human diseases and conditions Basel, Switzerland, July 15, 2014 - Novartis announced that its eye care division…...